SC
ALXN

Scotia Capital’s Alexion Pharmaceuticals ALXN Stock Holding History

Scotia Capital’s Portfolio ALXN Stock Details ALXN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-5,270
Closed -$603K – 801
2020
Q3 		$603K Buy
+5,270
New +$569K 0.01% 471
2015
Q2 		– Sell
-4,347
Closed -$754K – 768
2015
Q1 		$754K Buy
+4,347
New +$787K 0.02% 358
2014
Q4 		– Sell
-4,123
Closed -$684K – 627
2014
Q3 		$684K Buy
+4,123
New +$677K 0.01% 368

Other funds holding ALXN

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
LSV Asset Management
LSV Asset Management Chicago, Illinois $55.1B AUM 45.38% 1-Year Est. Return

Scotia Capital's ALXN Position: Q4 2020 in Review

Scotia Capital sold out of Alexion Pharmaceuticals (ALXN) in Q4 2020, closing a stake of 5,270 shares — an estimated $603K sold.

Scotia Capital first reported a position in ALXN in Q3 2014 and held it in 3 quarters. The position peaked at $754K in Q1 2015. 827 funds tracked by Wall St. Rank hold ALXN as of Q4 2020.

  • Scotia Capital reported no remaining Alexion Pharmaceuticals position as of Q4 2020 after selling out during the quarter.
  • Scotia Capital sold 5,270 Alexion Pharmaceuticals shares in Q4 2020, an estimated $603K.
  • Scotia Capital first reported a position in Alexion Pharmaceuticals in Q3 2014 and held it in 3 quarters.
  • Scotia Capital's Alexion Pharmaceuticals position peaked at $754K in Q1 2015.
  • 827 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q4 2020.

Based on Scotia Capital's 13F filing for Q4 2020, filed 11 Feb 2021.